Mesothelin targeted cancer immunotherapy

被引：253

作者：

Hassan, Raffit ^{[1
]}

Ho, Mitchell ^{[2
]}

机构：

[1] NCI, Solid Tumor Immunotherapy Sect, Mol Biol Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA

[2] NCI, Mol Biol Sect, Mol Biol Lab, Canc Res Ctr,NIH, Bethesda, MD 20892 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2008年 / 44卷 / 01期

关键词：

mesothelioma; ovarian cancer; pancreatic cancer; lung cancer; tumour vaccine; monoclonal antibodies; clinical trial; CA-12; SS1P; MORAb-009;

D O I：

10.1016/j.ejca.2007.08.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesothelin is a tumour differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. It is, however, highly expressed in several huzman cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma. The normal biologic function of mesothelin is unknown but recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy. Three mesothelin targeted agents are in various stages of clinical evaluation in patients. These include SS1P (CAT-5001) a recombinant immunotoxin targeting mesothelin, MORAb-009 a chimeric anti-mesothelin monoclonal antibody and CRS-207 a live-attenuated Listeria monocytogenes vector encoding human mesothelin. These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy. Published by Elsevier Ltd.

引用

页码：46 / 53

页数：8

共 46 条

[1]

Argani P, 2001, CLIN CANCER RES, V7, P3862

[2]

Armstrong DK, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.07.3494

[3] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].

BAST, RC ;

KLUG, TL ;

STJOHN, E ;

JENISON, E ;

NILOFF, JM ;

LAZARUS, H ;

BERKOWITZ, RS ;

LEAVITT, T ;

GRIFFITHS, CT ;

PARKER, L ;

ZURAWSKI, VR ;

KNAPP, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887

[4] Mesothelin is not required for normal mouse development or reproduction [J].

Bera, TK ;

Pastan, I .

MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (08) :2902-2906

[5] Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy [J].

Breidenbach, M ;

Rein, DT ;

Everts, M ;

Glasgow, JN ;

Wang, M ;

Passineau, MJ ;

Alvarez, RD ;

Korokhov, N ;

Curiel, DT .

GENE THERAPY, 2005, 12 (02) :187-193

[6] Listeria-based cancer vaccines that segregate immunogenicity from toxicity [J].

Brockstedt, DG ;

Giedlin, MA ;

Leong, ML ;

Bahjat, KS ;

Gao, Y ;

Luckett, W ;

Liu, WQ ;

Cook, DN ;

Portnoy, DA ;

Dubensky, TW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (38) :13832-13837

[7]

BROCKSTEDT DG, 2007, AACR P APR 14

[8] ISOLATION AND CHARACTERIZATION OF A MONOCLONAL-ANTIBODY, K1, REACTIVE WITH OVARIAN CANCERS AND NORMAL MESOTHELIUM [J].

CHANG, K ;

PASTAN, I ;

WILLINGHAM, MC .

INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (03) :373-381

[9] MONOCLONAL-ANTIBODY K1 REACTS WITH EPITHELIAL MESOTHELIOMA BUT NOT WITH LUNG ADENOCARCINOMA [J].

CHANG, K ;

PAI, LH ;

PASS, H ;

POGREBNIAK, HW ;

TSAO, MS ;

PASTAN, I ;

WILLINGHAM, MC .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1992, 16 (03) :259-268

[10] Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers [J].

Chang, K ;

Pastan, I .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (01) :136-140

← 1 2 3 4 5 →